https://www.selleckchem.com/products/tl13-112.html
Both class-I and class-II neoantigen loads from SNM and INDEL were found to predict overall survival independent of tumor mutational burden (TM, breast cancer subtypes, tumor-infiltrating lymphocyte (TIL) levels, tumor stage, and age at diagnosis. Our study highlighted the importance of accurate and comprehensive neoantigen profiling and QC, and is the first to report the predictive value of neoantigen load for overall survival in breast cancer.Background T cells expressing a chimeric antigen receptor (CAR) engineered to target CD19
Like
Comment
Share
